Comparative Pharmacology
Head-to-head clinical analysis: FINGOLIMOD versus GILENYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FINGOLIMOD versus GILENYA.
FINGOLIMOD vs GILENYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sphingosine 1-phosphate receptor modulator; acts as a functional antagonist by downregulating S1P receptors on lymphocytes, preventing their egress from lymph nodes and reducing peripheral lymphocyte count.
Fingolimod is a sphingosine 1-phosphate receptor modulator. It is phosphorylated to fingolimod-phosphate, which binds to S1P receptors 1, 3, 4, and 5. It blocks lymphocyte egress from lymph nodes by acting as a functional antagonist at S1P1 receptors, reducing peripheral blood lymphocyte count and central nervous system inflammation.
0.5 mg orally once daily
0.5 mg orally once daily, with or without food
None Documented
None Documented
Terminal elimination half-life is 6–9 days due to enteropathic recirculation and high Vd; clinical context: steady state reached in 1–2 months, duration of immunosuppression persists for weeks after discontinuation.
Clinical Note
moderateFingolimod + Fluconazole
"The metabolism of Fluconazole can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Doxycycline
"The metabolism of Doxycycline can be decreased when combined with Fingolimod."
Clinical Note
moderateFingolimod + Isavuconazonium
The terminal elimination half-life of fingolimod is approximately 6–9 days (mean 8.4 days). Due to the prolonged half-life, steady-state is achieved after 1–2 months of daily dosing, and lymphopenia may persist for up to 2 months after treatment cessation.
Primarily via biliary/fecal excretion (81% of dose recovered in feces as metabolites); renal excretion accounts for <2.5% of unchanged drug.
Fingolimod is primarily eliminated via fecal excretion (81%) and to a lesser extent via renal excretion (<1% as unchanged drug). Biliary excretion accounts for a minor portion. The major metabolic pathway is via CYP4F2-mediated hydroxylation, followed by glucuronidation and elimination in feces.
Category C
Category C
Sphingosine 1-Phosphate Receptor Modulator
Sphingosine 1-Phosphate Receptor Modulator
"The metabolism of Isavuconazonium can be decreased when combined with Fingolimod."